Reply to Beechar et al. “Donor-Derived Infections: A Journey From Evidence to Policy”
2024

Reply to Beechar et al. on Donor-Derived Infections

Sample size: 6 publication Evidence: low

Author Information

Author(s): Carl Boodman, Oscar Fernandez Garcia, Dima Kabbani, Armelle Perez Cortes Villalobos, Johan van Griensven, Karen Doucette

Primary Institution: University of Manitoba

Hypothesis

The necessity of evaluating the consequences of screening high-risk solid organ transplant donors and recipients for Bartonella quintana infection.

Conclusion

The authors emphasize the need for more data and propose a system to screen and monitor individuals at elevated risk of donor-derived B quintana infection.

Supporting Evidence

  • B quintana is treatable, and screening should not delay organ transplantation.
  • Cases of donor-derived B quintana have been identified in multiple jurisdictions.
  • B quintana endocarditis has a fatality rate of approximately 10% despite treatment.
  • Guideline recommendations should be based on robust studies, but data on emerging diseases is often lacking.

Takeaway

This study talks about a disease that can be passed from organ donors to transplant patients and suggests ways to check for it so that patients can be treated quickly.

Methodology

The authors propose a combination of different diagnostic tests and epidemiologic risk factors to identify individuals at high risk of B quintana infection.

Potential Biases

The opinion expressed may be limited by circular reasoning regarding the evidence base for an emerging disease.

Limitations

Robust data on B quintana infection is limited, especially for neglected infections linked to poverty.

Participant Demographics

The study discusses cases primarily from Alberta, Canada, involving organ transplant recipients.

Digital Object Identifier (DOI)

10.1093/ofid/ofae671

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication